Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: Studies with human THP-1 monocytes and J774 murine macrophages

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5747-5760

  Peyrusson, Frédéric ^a   Butler, Deborah ^b   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; DAPTOMYCIN; FUSIDIC ACID; GEMFIBROZIL; LACTATE DEHYDROGENASE; LANOPEPDEN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OXACILLIN; TIGECYCLINE; VANCOMYCIN; VERAPAMIL; FUSED HETEROCYCLIC RINGS; HYDROXAMIC ACID;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CELL ORGANELLE; CELL VIABILITY; CELLULAR DISTRIBUTION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG DISPOSITION; HOMOGENATE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; MONOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; PATHOGENICITY;

ANIMALS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; HUMANS; HYDROXAMIC ACIDS; MACROPHAGES; MICE; MONOCYTES; STAPHYLOCOCCUS AUREUS;

EID: 84940920132     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00827-15     Document Type: Article

References (57)

1. Tarai B, Das P, Kumar D. 2013. Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options. J Lab Physicians 5:71-78. http://dx.doi.org/10.4103/0974-2727.119843.
2. Chung DR, Huh K. 2015. Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia. Expert Rev Anti Infect Ther 13:197-207. http://dx.doi.org/10.1586/14787210.2015.999668.
3. Wolkewitz M, Frank U, Philips G., Schumacher M, Davey P. 2011. Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother 66:381-386. http://dx.doi.org/10.1093/jac/dkq424.
4. Lowy FD. 2000. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 8:341-343. http://dx.doi.org/10.1016/S0966-842X(00)01803-5.
5. Sinha B, Herrmann M. 2005. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb Haemost 94:266-277.
6. Sinha B, Fraunholz M. 2010. Staphylococcus aureus host cell invasion and post-invasion events. Int J Med Microbiol 300:170-175. http://dx.doi.org/10.1016/j.ijmm.2009.08.019.
7. Wright JA, Nair SP 2010. Interaction of staphylococci with bone. Int J Med Microbiol 300:193-204. http://dx.doi.org/10.1016/j.ijmm.2009.10.003.
8. Clement S, Vaudaux P, Francois P., Schrenzel J, Huggler E, Kampf S., Chaponnier C, Lew D, Lacroix JS 2005. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 192:1023-1028. http://dx.doi.org/10.1086/432735.
9. Bosse MJ, Gruber HE, Ramp WK 2005. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. J Bone Joint Surg Am 87:1343-1347.
10. Zautner AE, Krause M, Stropahl G., Holtfreter S, Frickmann H, Maletzki C., Kreikemeyer B, Pau HW, Podbielski A. 2010. Intracellular persisting Staphylococcus aureus is the major pathogen in recurrent tonsillitis. PLoS One 5:e9452. http://dx.doi.org/10.1371/journal.pone.0009452.
11. Van Bambeke F., Barcia-Macay M, Lemaire S., Tulkens PM. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Devel 9:218-230.
12. Mazel D, Pochet S, Marliere P. 1994. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 13:914-923.
13. Lewandowski T, Huang J, Fan F., Rogers S, Gentry D, Holland R., Demarsh P, Aubart K, Zalacain M. 2013. Staphylococcus aureus formylmethionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity. Antimicrob Agents Chemother 57:2929-2936. http://dx.doi.org/10.1128/AAC.00162-13.
14. Sutcliffe JA. 2011. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241:122-152. http://dx.doi.org/10.1111/j.1749-6632.2011.06323.x.
15. Chen DZ, Patel DV, Hackbarth C.J., Wang W., Dreyer G, Young DC, Margolis P.S., Wu C., Ni ZJ, Trias J, White RJ, Yuan Z. 2000. Actinonin, a naturally occurring antibacterial agent, isa potent deformylase inhibitor. Biochemistry 39:1256-1262. http://dx.doi.org/10.1021/bi992245y.
16. O'Dwyer K., Hackel M, Hightower S., Hoban D, Bouchillon S, Qin D., Aubart K, Zalacain M, Butler D. 2013. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother 57:2333-2342. http://dx.doi.org/10.1128/AAC.02566-12.
17. Corey R, Naderer OJ, O'Riordan WD, Dumont E, Jones L.S., Kurtinecz M., Zhu JZ. 2014. Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 58:6518-6527. http://dx.doi.org/10.1128/AAC.03360-14.
18. Vallet CM, Marquez B, Ngabirano E., Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2011. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. Int J Antimicrob Agents 38:249-256.
19. Carlier MB, Scorneaux B, Zenebergh A., Desnottes JF, Tulkens PM. 1990. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 26(Suppl B):27-39. http://dx.doi.org/10.1093/jac/26.suppl-B.27.
20. Seral C, Van Bambeke F, Tulkens PM. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 47: 2283-2292. http://dx.doi.org/10.1128/AAC.47.7.2283-2292.2003.
21. Barcia-Macay M., Seral C, Mingeot-Leclercq MP, Tulkens P.M., Van Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841-851. http://dx.doi.org/10.1128/AAC.50.3.841-851.2006.
22. Peyrusson F, Huys G, Van Bambeke F, Butler G, Tulkens PM 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother [ICAAC], Washington, DC, 5 to 9 September 2014, poster A-686.
23. Peyrusson F, Tulkens PM, Van Bambeke F. 2014. Abstr 24th Eur Congr Clin Microbiol Infect Dis [ECCMID], Barcelona, Spain, 10 to 13 May 2014, electronic poster eP185 with oral presentation.
24. Tsuchiya S, Yamabe M, Yamaguchi Y., Kobayashi Y, Konno T, Tada K. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26:171-176. http://dx.doi.org/10.1002/ijc.2910260208.
25. Snyderman R, Pike MC, Fischer D.G., Koren HS. 1977. Biologic and biochemical activities of continuous macrophage cell lines P388D1 and J774.1. J Immunol 119:2060-2066.
26. Renard C, Vanderhaeghe HJ, Claes P.J., Zenebergh A., Tulkens PM. 1987. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrob Agents Chemother 31:410-416. http://dx.doi.org/10.1128/AAC.31.3.410.
27. Scorneaux B, Ouadrhiri Y, Anzalone G., Tulkens PM. 1996. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother 40:1225-1230.
28. Kosowska-Shick K., Clark C, Credito K., McGhee P, Dewasse B, Bogdanovich T., Appelbaum PC. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 50:765-769. http://dx.doi.org/10.1128/AAC.50.2.765-769.2006.
29. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos G.M., Wennersten C., Venkataraman L, Moellering RC, Ferraro MJ 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208. http://dx.doi.org/10.1016/S0140-6736(01)05410-1.
30. Baudoux P, Lemaire S, Denis O., Tulkens PM, Van Bambeke F, Glupczynski Y. 2010. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 65:1228-1236. http://dx.doi.org/10.1093/jac/dkq110.
31. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters (version 5.0). European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org. Last updated, 26 January 2015; last accessed, 30 January 2015.
32. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement (MS100-S24). Clinical and Laboratory Standards Institute, Wayne, PA.
33. Lemaire S, Kosowska-Shick K, Appelbaum P.C., Glupczynski Y., Van Bambeke F, Tulkens PM. 2011. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. J Antimicrob Chemother 66:596-607. http://dx.doi.org/10.1093/jac/dkq478.
34. Buyck J, Lemaire S, Seral C., Anantharajah A, Peyrusson F, Tulkens P.M., Van Bambeke F. 2015. In vitro models for the study of the intracellular activity of antibiotics, p 147-157. In Michiels J, Fauvart M (ed), Bacterial persistence (Molecular Biology Laboratory Protocols Series). Humana Press (Springer), New York, NY.
35. Lemaire S, Van Bambeke F, Tulkens PM. 2009. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, anovelfluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 53:3734-3743. http://dx.doi.org/10.1128/AAC.00203-09.
36. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM 2009. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 64:1035-1043. http://dx.doi.org/10.1093/jac/dkp267.
37. Lemaire S, Glupczynski Y, Duval V., Joris B, Tulkens PM, Van Bambeke F. 2009. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:2289-2297. http://dx.doi.org/10.1128/AAC.01135-08.
38. Mélard A., Garcia LG, Das D, Rozenberg R., Tulkens PM, Van Bambeke F, Lemaire S. 2013. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. J Antimicrob Chemother 68:648-658. http://dx.doi.org/10.1093/jac/dks442.
39. Seral C, Michot JM, Chanteux H, Mingeot-Leclercq MP, Tulkens P.M., Van Bambeke F. 2003. Influence of p-glycoprotein inhibitors on accumulation of macrolides in j774 murine macrophages. Antimicrob Agents Chemother 47:1047-1051. http://dx.doi.org/10.1128/AAC.47.3.1047-1051.2003.
40. Van Bambeke F., Carryn S, Seral C., Chanteux H, Tyteca D, Mingeot-Leclercq MP, Tulkens PM. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 48: 2853-2860. http://dx.doi.org/10.1128/AAC.48.8.2853-2860.2004.
41. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49:2429-2437. http://dx.doi.org/10.1128/AAC.49.6.2429-2437.2005.
42. Lowry OH, Rosebrough NJ, Farr A.L., Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
43. Lemaire S, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrob Agents Chemother 54:2540-2548. http://dx.doi.org/10.1128/AAC.01723-09.
44. Flanagan S, McKee EE, Das D, Tulkens P.M., Hosako H., Fiedler-Kelly J, Passarell J, Radovsky A., Prokocimer P. 2015. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 59:178-185. http://dx.doi.org/10.1128/AAC.03684-14.
45. Baudoux P, Bles N, Lemaire S., Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2007. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 59:246-253.
46. Lemaire S, Van Bambeke F, Pierard D, Appelbaum P.C., Tulkens PM. 2011. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis 52(Suppl 7):S493-S503. http://dx.doi.org/10.1093/cid/cir165.
47. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y., Tulkens PM. 2007. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 51:1627-1632. http://dx.doi.org/10.1128/AAC.01192-06.
48. Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Moller N. 2010. Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro. Antimicrob Agents Chemother 54:2391-2400. http://dx.doi.org/10.1128/AAC.01400-09.
49. Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Moller N. 2010. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. J Antimicrob Chemother 65:962-973. http://dx.doi.org/10.1093/jac/dkq052.
50. Bauer J, Siala W, Tulkens P.M., Van Bambeke F. 2013. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 57:2726-2737. http://dx.doi.org/10.1128/AAC.00181-13.
51. Lechner S, Lewis K, Bertram R. 2012. Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J Mol Microbiol Biotechnol 22:235-244. http://dx.doi.org/10.1159/000342449.
52. Singh R, Ray P, Das A., Sharma M. 2009. Role of persisters and smallcolony variants in antibiotic resistance of planktonic and biofilmassociated Staphylococcus aureus: an in vitro study. J Med Microbiol 58: 1067-1073. http://dx.doi.org/10.1099/jmm.0.009720-0.
53. Carlier MB, Zenebergh A, Tulkens PM 1987. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 20(Suppl B):47-56. http://dx.doi.org/10.1093/jac/20.suppl-B.47.
54. Carlier MB, Garcia-Luque I, Montenez J.P., Tulkens PM, Piret J. 1994. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React 16:211-220.
55. Sangshetti JN, Khan FAK, Shinde DB. 2015. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem 22:214-236.
56. Naderer OJ, Dumont E, Zhu J., Kurtinecz M, Jones LS. 2013. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 57: 2005-2009. http://dx.doi.org/10.1128/AAC.01779-12.
57. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Activity of three (beta)-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 55:897-904. http://dx.doi.org/10.1093/jac/dki094.